An Ebola outbreak tearing through eastern Democratic Republic of the Congo has become the second-largest in recorded history, with health authorities confirming more than 1,100 cases and 279 deaths as of late June — and warning that it is growing faster than any previous Ebola epidemic. The DRC Health Ministry reported 1,115 confirmed cases and 279 deaths, a case-fatality rate of about 25 percent, with 130 people recovered.
The epidemic is concentrated in Ituri province, which has logged 997 confirmed cases and 226 deaths across 22 health zones. North Kivu has reported 94 cases and 50 deaths, and South Kivu three cases. The virus has also crossed international borders: Uganda has confirmed 20 cases and two deaths, and a single imported case was detected in France, underscoring how quickly modern travel can carry the disease far from its source.
Crucially, this outbreak is caused by the Bundibugyo species of Ebola virus, a rarer strain than the Zaire ebolavirus responsible for most major epidemics. That distinction is at the heart of why this outbreak is so dangerous. There is no licensed vaccine or specific antiviral treatment for Bundibugyo, and on May 28 the World Health Organization recommended against deploying the rVSV-ZEBOV vaccine — the shot that helped contain recent outbreaks — citing insufficient evidence that it offers cross-protection against this strain.
The WHO declared the outbreak a Public Health Emergency of International Concern on May 16, its highest level of alarm, reserved for events that threaten to spread across borders and demand a coordinated international response. Investigators believe the virus spilled into humans around mid-to-late February in Mongbwalu, a gold-mining town in Ituri, where dense, transient populations of miners and traders created ideal conditions for early, undetected transmission.
Several factors are driving the rapid spread. Ituri is a commercial and migratory hub, with constant movement of people and goods that carries the virus between communities. The region is also gripped by armed conflict and a wider humanitarian crisis, with large-scale displacement that hampers contact tracing, disrupts treatment and makes it dangerous for health workers to reach affected areas — the same volatile mix that has frustrated past responses in eastern Congo.
Without a vaccine to build a protective ring around cases, responders are leaning on the oldest tools in the outbreak playbook: surveillance, contact tracing, safe burials, isolation of the sick and community engagement to counter mistrust. The WHO and partners including Doctors Without Borders have been racing to strengthen those measures and to test promising experimental vaccine and treatment candidates against the Bundibugyo strain.
This is the 17th Ebola outbreak in the Democratic Republic of the Congo, the country where the virus was first identified in 1976, but its trajectory has alarmed even veteran responders because of how quickly case numbers have climbed. The central question now is whether surveillance and containment can outpace a virus moving through a region where conflict, poverty and population movement all work in its favor — and whether experimental countermeasures can be validated and deployed before the outbreak grows larger still.